DaVita Inc. (NYSE:DVA) Shares Sold by LSV Asset Management

LSV Asset Management decreased its position in shares of DaVita Inc. (NYSE:DVA) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,028,429 shares of the company’s stock after selling 25,400 shares during the period. LSV Asset Management owned 1.25% of DaVita worth $153,802,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. raised its position in shares of DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after buying an additional 275,284 shares during the last quarter. Amundi grew its position in DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after purchasing an additional 240,126 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in shares of DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after acquiring an additional 116,758 shares during the period. JPMorgan Chase & Co. raised its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company’s stock valued at $29,430,000 after buying an additional 84,375 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of a number of analyst reports. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Barclays boosted their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Up 6.4 %

DVA opened at $153.15 on Thursday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50 day simple moving average of $153.05 and a 200-day simple moving average of $156.75. The stock has a market capitalization of $12.25 billion, a P/E ratio of 14.26, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.